In conclusion, our pilot project found that a panel comprised of seven urinary biomarkers (8-hydroxyguanosine, dodecanal, leukotriene C4, α1-antitrypsin, IgA-uromodulin complex, galactose-deficient IgA1, and heparan sulfate) differentiated patients with IgAN from patients with other renal diseases and healthy controls. Here, IGHA1 is linked to kidney disorder.